(Q42999898)

12 November 2017

title

Different turnover rate of hepatitis C virus clearance by different treatment regimen using interferon-beta (English)

1 reference

12 November 2017

1 reference

Shiratori Y

1

1 reference

12 November 2017

Perelson AS

2

1 reference

12 November 2017

Weinberger L

3

1 reference

12 November 2017

Imazeki F

4

1 reference

12 November 2017

Yokosuka O

5

1 reference

12 November 2017

Nakata R

6

1 reference

12 November 2017

Ihori M

7

1 reference

12 November 2017

Hirota K

8

1 reference

12 November 2017

Ono N

9

1 reference

12 November 2017

Kuroda H

10

1 reference

12 November 2017

Motojima T

11

1 reference

12 November 2017

Nishigaki M

12

1 reference

12 November 2017

Omata M

13

1 reference

12 November 2017

publication date

1 August 2000

1 reference

12 November 2017

published in

Journal of Hepatology

1 reference

12 November 2017

volume

33

1 reference

12 November 2017

issue

2

1 reference

12 November 2017

page(s)

313-322

1 reference

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980373-6

7 January 2021

Clinical outcomes after transfusion-associated hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980373-6

7 January 2021

Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980373-6

7 January 2021

Discrepancy between biochemical and virological responses to interferon-alpha in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980373-6

7 January 2021

The treatment of chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980373-6

7 January 2021

Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980373-6

7 January 2021

Therapy of hepatitis C: overview

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980373-6

7 January 2021

Factors predictive of a beneficial response to therapy of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980373-6

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980373-6

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980373-6

7 January 2021

Permanent response to alpha-interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV-RNA from serum.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980373-6

7 January 2021

Loss of serum HCV RNA at week 4 of interferon‐α therapy is associated with more favorable long‐term response in patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980373-6

7 January 2021

Early hepatitis C virus-RNA responses predict interferon treatment outcomes in chronic hepatitis C. The Consensus Interferon Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980373-6

7 January 2021

Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980373-6

7 January 2021

HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980373-6

7 January 2021

Viral dynamics in human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980373-6

7 January 2021

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980373-6

7 January 2021

Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980373-6

7 January 2021

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980373-6

7 January 2021

Dynamics of hepatitis C viremia following interferon-alpha administration

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980373-6

7 January 2021

Antiviral actions of interferon interferon-regulated cellular proteins and their surprisingly selective antiviral activities

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980373-6

7 January 2021

Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980373-6

7 January 2021

Effects of interferon beta on non-A, non-B acute hepatitis: a prospective, randomized, controlled-dose study. Japan Acute Hepatitis Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980373-6

7 January 2021

Differences between interferon-alpha and -beta treatment for patients with chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980373-6

7 January 2021

Full-length sequence of a hepatitis C virus genome having poor homology to reported isolates: comparative study of four distinct genotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980373-6

7 January 2021

Significance of serum hepatitis C virus RNA levels in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980373-6

7 January 2021

Real-time monitoring of HCV-RNA by single tube assay kit and potential importance for predicting virological sustained response in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980373-6

7 January 2021

Quantitative assays for hepatitis C virus in serum as predictors of the long-term response to interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980373-6

7 January 2021

Prospective study of interferon therapy for compensated cirrhotic patients with chronic hepatitis C by monitoring serum hepatitis C RNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980373-6

7 January 2021

10.1016/S0168-8278(00)80373-6

Identifiers

DOI

1 reference

12 November 2017

1 reference